Format

Send to

Choose Destination
ACS Infect Dis. 2018 Feb 9;4(2):88-92. doi: 10.1021/acsinfecdis.7b00268. Epub 2018 Jan 3.

Combating Intracellular Pathogens with Repurposed Host-Targeted Drugs.

Author information

1
Department of Medicine, Division of Infectious Diseases and Geographic Medicine, and Department of Microbiology and Immunology, School of Medicine, Stanford University , 300 Pasteur Drive, Lane Building Rm L127, Stanford, California 94305, United States.

Abstract

There is a large, global unmet need for the development of countermeasures to combat intracellular pathogens. The development of novel antimicrobials is expensive and slow and typically focuses on selective inhibition of proteins encoded by a single pathogen, thereby providing a narrow spectrum of coverage. The repurposing of approved drugs targeting host functions required for microbial infections represents a promising alternative. This review summarizes progress and challenges in the repurposing of approved drugs as host-targeted broad-spectrum agents for the treatment of intracellular pathogens. These strategies include targeting both cellular factors required for infection by various viruses, intracellular bacteria, and/or protozoa as well as factors that modulate the host immune response to these microbial infections. The repurposed approach offers complementary means to develop therapeutics against existing and emerging intracellular microbial threats.

PMID:
29298032
PMCID:
PMC5807128
DOI:
10.1021/acsinfecdis.7b00268
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center